Key Investment Highlights 

Significant upside

Orthocell’s key products address markets worth more than US$10bn per annum and significant value upside potential exists for Orthocell, underpinned by its world leading diversified multiproduct portfolio of leading regenerative medicine products and recent M&A transactions executed in the sector. 

De-risked product portfolio

Orthocell’s product portfolio is significantly de-risked and supported by substantial clinical data, publications in leading journals, regulatory approvals and significant partner interest from the world’s largest healthcare companies.


Orthocell’s recent European regulatory approval (CE Mark) for CelGro® validates the CelGro® technology platform and can be leveraged for additional orthopaedic indications including bone, tendon, nerve and cartilage. (Click here for more information) 


Ortho-ATI® has extensive clinical validation with over 500 patients treated to date and clinical data up published in peer reviewed journals, demonstrating the world leading cell therapy reduces pain, repairs tendons and returns patients to work and activities of daily living.  In addition, Orthocell has a research collaboration in place with Johnson and Johnson and is generating significant partner interest. (Click here for more information)

Validated manufacturing facility and process

Orthocell’s Good Manufacturing Practice certified and Therapeutic Goods Administration licensed manufacturing facility underpin the Company’s competitive advantage and can be readily scaled to meet market demand.  

Credentialed and highly aligned leadership team

Orthocell is led by an experienced Board and management team, which have been responsible for the rapid development of the business. They have a successful track record of developing and commercialising novel healthcare and technology products.